AGC Biologics to Manufacture Peanut Allergy Vax Candidate

AGC Biologics, a biopharmaceutical CDMO, entered a partnership with Allergy Therapeutics, to manufacture clinical trial materials for Allergy Therapeutics’ virus-like particle (VLP)-based peanut allergy vaccine candidate.
 
AGC Biologics is supporting the manufacturing and testing of the VLP Peanut vaccine candidate, providing VLP material for Phase I supply. The FDA recently cleared Allergy Therapeutics Investigational New Drug application (IND), which included data generated in this collaborative effort and granted the VLP Peanut vaccine candidate a clear path to a Phase I product trial in the U.S.
 
“Allergy Therapeutics is creating a strong vaccine candidate for one of the most common food allergies in the world and we are proud to be helping bring it to this critical phase I trial phase,” said Jean-Baptiste Agnus, Chief Business Officer at AGC Biologics. “This is a shining example of the ability and expertise of our global network to handle some of the most complex products and support our clients advancing through important clinical phases.”
 
“This is another key milestone for our VLP Peanut vaccine candidate, and we believe AGC Biologics is a great partner for us as we enter the next stage of bringing this promising immunotherapy to market,” said Manuel Llobet, Chief Executive Officer, Allergy Therapeutics. “We are excited to demonstrate the potential of this vaccine to provide long-term protection and a long-lasting protective immune response.”
 
AGC Biologics is producing this vaccine material at its clinical and commercial manufacturing facility in Heidelberg, Germany. The site specializes in Microbial and Plasmid DNA (pDNA) offerings and is one of the company’s central facilities in Europe.